MCLD 2020
10th Edition
MASTER CLASS IN LIVER DISEASE & LTSI MIDTERM MEETING
LIVING DONOR LIVER TRANSPLANTATION
Transcending Barriers

DATES
FEB 28th TO MAR 1st, 2020

VENUE
ITC Grand Chola, Chennai, INDIA.

www.mclldindia.com
Dear Colleague,

It is a matter of great pleasure for me to introduce the 10th edition of the Master Class in Liver Disease series. This latest edition is planned as a three-day program on the 28th, 29th February and 1st March 2020 in Chennai, India. This meeting is being organized jointly in association with the Liver Transplant Society of India (LTSI), the pan-Indian organisation for liver transplant professionals.

The MCLD series was started in Chennai, India in 2009 as a way to teach and discuss current & relevant topics in liver disease in India & the Asian subcontinent. Over the last 10 years it has transformed into one of the most eagerly awaited annual academic gatherings for both experts and trainees in the field of hepatology and liver transplantation.

The title for the 10th edition is ‘Transcending Barriers in Living Donor Liver Transplantation’. The success of Living Donor liver transplantation has transformed and challenged long established practices in the field of Deceased Donor Liver Transplantation. During this edition, we hope to discuss and debate a wide range of challenges in current LDLT practice including 'too-sick to transplant' recipients, controversial indications, marginal live liver donors, and challenging postoperative situations. The first two days are planned as multi-disciplinary sessions and will concentrate on the evaluation and optimisation of recipients and the peri-operative care of donors & recipients. The last day is organized as four parallel sessions catering to the interests of adult & pediatric hepatologists, anesthesia-intensive care specialists and radiologist surgeons. As always, the faculty for the meeting includes a galaxy of world-renowned experts from India & abroad.

For the first time in MCLD, we are hosting a LTSI Consensus meeting on the management of Acute liver failure after yellow phosphorous poisoning (rat killer poisoning). This is fast becoming a major health care problem in Southern India, and there are no guidelines to help clinicians. A Multidisciplinary multi-centre expert panel consisting of hepatologists, intensivists and surgeons is currently preparing draft guidelines for the management of these patients. This draft document will be discussed on the third day afternoon and finalised for wide distribution. I would like to invite clinicians involved in the care of these patients to attend the meeting and help us in developing this important document.

Over the years, MCLD has become as well known for its culinary delights and hospitality as for its scientific content. The ITC Grand Chola in Central Chennai is once again the venue of the 2020 meeting and we hope you will be able to join us there- to discuss, debate & learn in a relaxed atmosphere!

Kind regards,
Mohamed Rela

MCLD2020 - LTSI midterm conference has been endorsed by

The scientific content of this meeting is eligible for CME points by the TNMC
Welcome address & Introduction to Day 1 by the course director

**Session 1 | 9.00AM : Setting it up**
- LDLT: where are we and how did we get there?
- Challenges in LDLT for the next decade
- Evolution of pediatric LDLT

Speaker: Mohamed Rela (INDIA)

**Session 2 | 10.00AM : Getting it right!**
- Going beyond MELD score- Do not forget clinical assessment
- Recipient with recent sepsis: Strategies and timing of transplantation
- LDLT for ACLF: Current status and worldwide experience
- Timing of transplantation in children with metabolic liver disease

Speaker: Claus Niemann (USA)

**Session 3 | 11.30AM : Acute liver failure**
- Are standard listing criteria for ALF relevant in the LDLT setting?
- Extra-corporeal therapies in ALF: Current status
- Defining the indications & expected outcomes of auxiliary liver transplantation for ALF?

Speaker: Subash Gupta (INDIA)

**Session 4 | 12.30AM : Liver disease and other organs**
- Gut function & microbiota in chronic liver disease and its impact on transplant outcomes
- Chronic encephalopathy in the recipient: Assessment & its impact on outcomes
- Assessment & Optimisation of the frail recipient

Speaker: SK Sarin (INDIA)

**Session 5 | 2.30PM : Panel discussion**
- Recipient with coronary artery disease

Speaker: Dharmesh Kapoor (INDIA)

**Session 6 | 3.00PM : Transplant oncology: HCC**
- Assessing tumor biology in HCC: State of the art
- Portal vein tumor thrombus & liver transplantation
- Management of recurrent HCC after liver transplant

Speaker: Vincenzo Mazzaferro (ITALY)

**Session 7 | 4.00PM : Transplant Oncology: Other tumors**
- LT for colorectal liver metastases
- LT for cholangiocarcinoma
- LT for neuro-endocrine tumors
- Hepatoblastoma: Guidelines for treatment

Speaker: Pal-Dag Line (NORWAY)
Introduction to the LTSI - MCLD joint meeting by the LTSI president

Session 8 | 9.00AM : The donor operation
Preoperative optimisation of donors with NAFLD- what is achievable & safe
Setting up a minimally invasive donor hepatectomy program
Lessons from Living donor kidney transplantation - Transparency & comparators
How do liver donors do in the long term?

Session 9 | 10.30AM : Ethics of donor selection
Achieving double equipoise in the era of broadening indications for LDLT
Feasibility & Safeguards for Altruistic donation- Lessons from Organ Donation around the world
Altruistic donation from patients undergoing elective surgery: A wild dream?

Session 10 | 11.30AM : Post-transplant issues & management
Acute mental state changes in the early post-transplant period
Morbidity associated with RRT in the postop period
Pre-operative CRE colonisation and post-transplant septic episodes

Session 11 | 1.30PM : Recipient operation
Collateral ligation & portal inflow modulation in LDLT
Can left lobe graft be the future of adult LDLT?
Early & late outcomes after LDLT in complete portal vein thrombosis
ABO incompatible liver transplantation: Current status

Session 12 | 3.00PM : Post-transplant issues & management II
Graft dysfunction after LDLT: SFSS or not SFSS!
Hepatic artery thrombosis after liver transplant: Is retransplant the only option?
Thrombocytopenia post LDLT

Session 13 | 4.00PM : Technical complications
Prevention & management of biliary strictures after LDLT
Portal venous complications after LDLT in adults
Portal venous complications after LDLT in children

Session 14 | 5.00PM : Panel discussion
Long term impact of early complications after LDLT

Session 15 | 5.30PM : Long term outcomes after LDLT
Long-term outcomes in children after liver transplantation
Post-transplant malignancies
Quality Assurance and Quality Control of the Liver Transplant service-line
DAY 3 - 1st MAR 2020

Consensus meeting on management of acute liver failure due to Rat killer poisoning (1PM-4PM)
Dr. Rela Institute and Medical Centre, an International Medical facility, is a quaternary care hospital dedicated to fostering and responding to the needs of a diverse patient population. Established under the formidable leadership of Prof. Mohamed Rela, a world-renowned surgeon in the field of Liver Surgery and Transplantation, this hospital houses one of the world’s largest dedicated liver intensive care units. The hospital is committed to being an internationally significant health care system with the state-of-the-art infrastructure.